ライフサイエンスコーパス: myopericarditis

1 ox vaccination, compared with other types of myopericarditis.

2 etiologies or other diseases associated with myopericarditis.

3 acute pericarditis (32%) than in those with myopericarditis (11%) or perimyocarditis (12%; P<0.001).

4 n age, 26.5 years), who presented with acute myopericarditis 7 to 19 days following vaccination.

5 However, the absolute rate of myocarditis or myopericarditis after SARS-CoV-2 mRNA vaccination was lo

6 ,734 primary vaccinees, 18 cases of probable myopericarditis after smallpox vaccination were reported

7 The risk of myopericarditis after vaccination might limit this optio

8 onfirmed cases and over 50 probable cases of myopericarditis after vaccination reported to the Depart

9 ther investigate the risks of myocarditis or myopericarditis after vaccination within smaller subgrou

10 is the observation that the observed rate of myopericarditis among primary vaccinees is 3.6-fold (95%

11 Acute myopericarditis (AMP) development after vaccination has

12 icarditis (aOR: 2.42; 95% CI: 1.31-4.46) and myopericarditis (aOR: 2.63; 95% CI: 1.76-3.93).

13 Of these, 67 developed myopericarditis at 10.4 +/- 3.6 days after vaccination.

14 e the risk of myocarditis, pericarditis, and myopericarditis between BNT162b2 and mRNA-1273.

15 During the study period, 3017 myocarditis/myopericarditis cases among 252 million mRNA-1273 recipi

16 Barre syndrome cases, (2) 0.3, 2.4, and 14.3 myopericarditis cases, (3) and 236.5, 1655.5, and 9932.8

17 he future, many more cases of post-vaccinial myopericarditis could be seen.

18 e case of encephalitis and 37 cases of acute myopericarditis developed after vaccination; all cases r

19 The background incidence of myopericarditis did not show statistical significance wh

20 s diagnosis of myocarditis, pericarditis, or myopericarditis during a hospitalization or an emergency

21 No cases of myopericarditis following smallpox vaccination were repo

22 Myopericarditis has been a rare or unrecognized event af

23 gnificantly increased risk of myocarditis or myopericarditis in the Danish population, primarily driv

24 Clinicians should consider myopericarditis in the differential diagnosis of patient

25 ld be aware that smallpox vaccine-associated myopericarditis is a real entity, and symptoms after vac

26 ugh many viruses have been reported to cause myopericarditis, it has been a rare or unrecognized even

27 tations ranged from arrhythmias to ischemia, myopericarditis/myocarditis, ventricular dysfunction to

28 itary personnel vaccinated against smallpox, myopericarditis occurred at a rate of 1 per 12 819 prima

29 p, 269 participants developed myocarditis or myopericarditis, of whom 108 (40%) were 12-39 years old

30 clinical outcomes (hospital readmission for myopericarditis, other cardiovascular events, all-cause

31 The observed incidence (16.11/100,000) of myopericarditis over a 30-day observation window among 3

32 incidence of at least 140 clinical cases of myopericarditis per million primary smallpox vaccination

33 resent article is to assess the prognosis of myopericarditis/perimyocarditis in a multicenter, prospe

34 The natural history of myopericarditis/perimyocarditis is poorly known, and rec

35 nction was achieved in >90% of patients with myopericarditis/perimyocarditis.

36 s or a myopericardial inflammatory syndrome (myopericarditis/perimyocarditis; 85% idiopathic, 11% con

37 Myocarditis/myopericarditis rates were not higher than expected for

38 with steroids may be uniquely beneficial in myopericarditis related to smallpox vaccination, compare

39 derna global safety database for myocarditis/myopericarditis reports among mRNA-1273 recipients world

40 Myocarditis/myopericarditis reports from 18 December 2020 to 15 Febr

41 Myopericarditis should be considered an expected adverse

42 Post-vaccinial myopericarditis should be considered in patients with ch

43 The primary outcome, myocarditis or myopericarditis, was defined as a combination of a hospi

44 21-43 years with confirmed or probable acute myopericarditis were detected following vaccination of 4

45 fizer-BioNTech), 48 developed myocarditis or myopericarditis within 28 days from the vaccination date

46 -1273 (Moderna), 21 developed myocarditis or myopericarditis within 28 days from vaccination date (ad